Atalaya Capital Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Atalaya Capital Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40,000	Closed	-$404K	–	296
2022 Q4	$404K	Hold	40,000	–	–	0.07%	118
2022 Q3	$397K	Hold	40,000	–	–	0.05%	163
2022 Q2	$391K	Hold	40,000	–	–	0.05%	174
2022 Q1	$390K	Hold	40,000	–	–	0.04%	201
2021 Q4	$388K	Hold	40,000	–	–	0.04%	217
2021 Q3	$387K	Hold	40,000	–	–	0.06%	156
2021 Q2	$386K	Buy	+40,000	New	+$393K	0.1%	146

Atalaya Capital Management's EBAC Position: Q1 2023 in Review

Atalaya Capital Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 40,000 shares — an estimated $404K sold.

Atalaya Capital Management first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $404K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Atalaya Capital Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Atalaya Capital Management sold 40,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $404K.
Atalaya Capital Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Atalaya Capital Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $404K in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Atalaya Capital Management's 13F filing for Q1 2023, filed 11 May 2023.